Three years' experience with homologous central limbo-keratoplasty in the treatment of limbal stem cell deficiency

被引:28
作者
Sundmacher, R [1 ]
Reinhard, T [1 ]
Althaus, C [1 ]
机构
[1] Univ Dusseldorf, Augenklin, D-40225 Dusseldorf, Germany
来源
OPHTHALMOLOGE | 1997年 / 94卷 / 12期
关键词
limbal stem cell deficiency; central limbo-keratoplasty; cyclosporin A;
D O I
10.1007/s003470050218
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: Problems with epithelial healing are the main cause of corneal graft failure in patients with limbal stem cell deficiency. This post-operative complication cannot be eliminated by conventional penetrating keratoplasty alone, but only by additional limbal grafting, which is, however, highly immunogenic. We report here our 3 years' experience with a new surgical procedure which we developed called homologous central limbo-keratoplasty. Patients and methods: We have performed 52 homologous central limbo-keratoplasties in patients with limbal stem cell deficiency since February 1993. We report here the results of the first 18 transplantations with the longest follow-up periods (mean 22 months). The unmatched donor cornea was trephined in a way such that 40 % of its circumference contained limbus. These grafts were then sutured centrally into the host cornea. Systemic cyclosporin A (CSA) was administered for at least 1 year after all transplantations. Results: Fourteen of the 18 grafts failed during the follow-up period. The reasons for graft failure were severe surface disorders (7), severe surface disorders in combination with endothelial immune reactions (5) and endothelial immune reactions alone (2). The four patients with centrally clear grafts no longer receive systemic CSA with follow-up periods between 20 and 30 months. Conclusions: Central limbo-keratoplasty is a very promising procedure. However, the average results are not yet satisfying, because the majority of limbal stem cells undergo rejection within 2 years. Improved results will be achievable in the future by using well-matched instead of non-matched transplants and by further improving immune modulation beyond the effectiveness of current CSA treatment.
引用
收藏
页码:897 / 901
页数:5
相关论文
共 17 条
[1]  
ALLREDGE OC, 1981, ARCH OPHTHALMOL-CHIC, V99, P599
[2]  
CHEN JJY, 1990, INVEST OPHTH VIS SCI, V31, P1301
[3]  
DUKEELDER S, 1965, SYSTEM OPHTHALMOLOGY, V8, P648
[4]  
HANNA C, 1962, ARCH OPHTHALMOL-CHIC, V68, P810
[5]  
HOPPELER T, 1993, K DG2, P429
[6]  
HUANG AJW, 1991, INVEST OPHTH VIS SCI, V32, P96
[7]  
KENYON KR, 1989, OPHTHALMOLOGY, V96, P709
[8]  
Kruse F. E., 1996, Ophthalmologe, V93, P633
[9]  
Kuckelkorn R., 1993, Ophthalmologe, V90, P683
[10]   Systemic cyclosporin A prophylaxis after keratoplasties with an elevated risk for immune reactions as the only elevated risk factor [J].
Reinhard, T ;
Sundmacher, R ;
Godehardt, E ;
Heering, P .
OPHTHALMOLOGE, 1997, 94 (07) :496-500